395 related articles for article (PubMed ID: 32710318)
1. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
Xue F; He X
Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
[TBL] [Abstract][Full Text] [Related]
2. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
6. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
7. Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region.
Pramanik R; Arora S; Sharma P; Biswas A; Nayak B; Thakar A; Sharma A; Ghose S
J Med Virol; 2022 Feb; 94(2):720-728. PubMed ID: 34750844
[TBL] [Abstract][Full Text] [Related]
8. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
[TBL] [Abstract][Full Text] [Related]
9. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study.
Chen QY; Tang QN; Tang LQ; Chen WH; Guo SS; Liu LT; Li CF; Li Y; Liang YJ; Sun XS; Guo L; Mo HY; Sun R; Luo DH; Fan YY; He Y; Chen MY; Cao KJ; Qian CN; Guo X; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):701-711. PubMed ID: 28707462
[TBL] [Abstract][Full Text] [Related]
13. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
[TBL] [Abstract][Full Text] [Related]
14. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
Chan KC
Chin J Cancer; 2014 Dec; 33(12):598-603. PubMed ID: 25418194
[TBL] [Abstract][Full Text] [Related]
15. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
[TBL] [Abstract][Full Text] [Related]
16. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
[TBL] [Abstract][Full Text] [Related]
18. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
20. Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation.
Peng L; Yang Y; Guo R; Mao YP; Xu C; Chen YP; Sun Y; Ma J; Tang LL
Cancer Med; 2018 Dec; 7(12):5988-5998. PubMed ID: 30378277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]